Nolato AB AI Stock Analysis
Want to see SE:NOLA.B full AI Analyst Report?
Nolato AB (NOLA.B) AI Stock Analysis
Nolato AB
(Nasdaq OMX AB:NOLA.B)
Robust financials with minimal leverage and reliable cash generation form the primary support, reinforced by positive earnings call developments in medical solutions. Weak technical momentum from low RSI and negative MACD is the main drag on the overall score.
Nolato AB (NOLA.B) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 1.33B
- Dividend Yield
- 3.23%
- Average Volume (3M)
- 222.81K
- Price to Earnings (P/E)
- 21.1
- Beta (1Y)
- 0.69
- Revenue Growth
- 0.11%
- EPS Growth
- -14.70%
- Country
- Sweden
- Employees
- 5,692
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Industrial - Specialties
Nolato AB Business Overview & Revenue Model
Company Description
Nolato AB (publ) is a Swedish enterprise that specializes in the creation, manufacturing, and commercialization of polymer-based products, utilizing plastics, silicones, and thermoplastic elastomers. Its extensive portfolio serves a diverse array of...
How the Company Makes Money
Nolato makes money mainly by acting as a contract manufacturer and development partner, earning revenue from producing and supplying customer-specific polymer components, subassemblies, and finished products. Its core revenue streams typically includ...
Nolato AB Earnings Call Summary
The call was broadly positive, with 15 highlights versus 11 lowlights. Nolato reported group sales growth, strong Medical Solutions and Materials performance, strategic acquisitions, improved operating cash flow, and a strong financial position. These positives were moderated by lower group and business-area margins, continued medical ramp-up costs, automotive weakness expected to persist in Q4, lower Hygiene volumes, and elevated intragroup costs.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For full year 2026, CapEx is expected to be SEK 600 million to SEK 650 million; the effective tax rate is normalized to around 23%; no headwind is expected in Q4 from raw material pricing if the present situation is remaining; the ramp-up of larger projects is expected to continue going forward some quarters, but is expected to be getting better and better; the automotive headwind will remain in the fourth quarter, while how it looks further on remains uncertain; and the ongoing rate for costs outside the business areas is expected to be somewhere in between the SEK 9 million and the SEK 15 million per quarter.
Nolato AB Financial Statement Overview
Summary
Strong balance sheet with very low debt-to-equity of 0.13 and solid operating cash flow of 1.15 billion underpin stability, though multi-year revenue decline limits top-line momentum.
Income Statement
64PositiveBalance Sheet
91Very PositiveCash Flow
73Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.58B | 9.46B | 9.66B | 9.55B | 10.77B | 11.61B |
| Gross Profit | 1.74B | 1.73B | 1.61B | 1.34B | 1.43B | 1.82B |
| EBITDA | 1.37B | 1.59B | 1.51B | 1.28B | 1.48B | 1.92B |
| Net Income | 673.00M | 777.00M | 658.00M | 435.00M | 697.00M | 1.16B |
Balance Sheet | ||||||
| Total Assets | 11.18B | 9.28B | 9.69B | 9.30B | 10.01B | 10.05B |
| Cash, Cash Equivalents and Short-Term Investments | 584.00M | 482.00M | 672.00M | 688.00M | 1.01B | 1.45B |
| Total Debt | 749.00M | 1.45B | 1.53B | 1.88B | 2.03B | 1.79B |
| Total Liabilities | 5.21B | 3.75B | 3.95B | 4.13B | 4.62B | 5.29B |
| Stockholders Equity | 5.97B | 5.53B | 5.74B | 5.17B | 5.39B | 4.77B |
Cash Flow | ||||||
| Free Cash Flow | 752.00M | 278.00M | 742.00M | 355.00M | -49.00M | 446.00M |
| Operating Cash Flow | 1.15B | 1.06B | 1.38B | 781.00M | 406.00M | 1.23B |
| Investing Cash Flow | -1.13B | -788.00M | -636.00M | -444.00M | -451.00M | -782.00M |
| Financing Cash Flow | -15.00M | -390.00M | -798.00M | -631.00M | -487.00M | -634.00M |
Nolato AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:NOLA.B, the sentiment is Neutral. The current price of 52.70 is below the 20-day moving average (MA) of 53.85, below the 50-day MA of 54.19, and above the 200-day MA of 50.60, indicating a neutral trend. The MACD of -0.76 indicates Positive momentum. The RSI at 44.36 is Neutral, neither overbought nor oversold. The STOCH value of 82.05 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:NOLA.B.
Nolato AB Peers Comparison
Overall Rating
SE:LIFCO.B75Outperform
SE:ALIF.B74Outperform
SE:ARJO.B69Neutral
SE:NOLA.B65Neutral
SE:XVIVO64Neutral
SE:BERG.B61Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 75Outperform | SEK 131.90B | 33.53 | 19.26% | 0.93% | 7.11% | 10.47% | |
| 74Outperform | SEK 22.21B | 34.62 | 11.32% | 0.82% | 1.62% | 63.45% | |
| 69Neutral | SEK 9.96B | 27.49 | 4.65% | 2.60% | -0.50% | -17.58% | |
| 65Neutral | SEK 14.20B | 21.08 | 11.69% | 3.23% | 0.11% | -14.70% | |
| 64Neutral | SEK 6.49B | 50.37 | 5.89% | ― | 17.83% | 330.94% | |
| 61Neutral | SEK 6.92B | 26.28 | 13.53% | 1.61% | 1.00% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:NOLA.B | Nolato AB Class B | 52.70 | -4.16 | -7.32% | |
| SE:LIFCO.B | Lifco Ab | 290.40 | -54.51 | -15.80% | |
| SE:ALIF.B | AddLife AB Class B | 182.10 | 3.65 | 2.05% | |
| SE:ARJO.B | Arjo AB Class B | 36.56 | 7.01 | 23.72% | |
| SE:XVIVO | Xvivo Perfusion AB | 206.00 | 42.50 | 25.99% | |
| SE:BERG.B | Bergman & Beving AB Class B | 261.00 | -40.38 | -13.40% |
Nolato AB Corporate Events
Nolato lifts sales on Medtech strength but margins tighten amid higher costs
Nolato reported third-quarter 2026 sales of SEK 2.5 billion, up 7% year-on-year, with organic growth of 3% in a challenging market but a lower EBITA margin of 10.2% due to higher input costs. For the first nine months, sales edged up to SEK 7.3 billi...
Nolato Sets October 29 Webcast for Q3 2026 Interim Report
Nolato AB will release its interim report for the third quarter of 2026 on Thursday, October 29, at 7:45 a.m. CET, followed by an English-language webcast conference call at 8:45 a.m. CET led by President and CEO Anders Björklund and CFO Per-Ola Holm...
Nolato names Cecilia Hellner to lead Engineered Solutions
Nolato has appointed Cecilia Hellner as Head of the Engineered Solutions business area and a member of Group Management, following a recruitment process initiated after former area head Anders Björklund became President and CEO. Hellner, currently Ma...
Nolato sharpens portfolio with medtech acquisitions and Romanian exit
Nolato is accelerating its push into electronics-intensive medical technology and advanced manufacturing through the acquisitions of Unitron and M&M Qualtech, while simultaneously exiting its Romanian operation. These moves expand the group’s capabil...
Nolato boosts Medical Solutions arm with acquisition of Dutch CDMO Unitron
Nolato AB has agreed to acquire Dutch medical technology CDMO Unitron, an innovator with over 30 years’ experience and annual sales of around SEK 200 million, in a move that broadens its Medical Solutions business. Unitron, which operates in the Neth...
Nolato boosts electronics capacity with acquisition of Ireland’s M&M Qualtech
Nolato AB has agreed to acquire Irish electronics specialist M&M Qualtech, a Galway-based company with around 200 employees and estimated annual sales of approximately SEK 385 million in 2026, financed through Nolato’s own cash and existing credit fa...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
